# Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

> **NCT00566852** · PHASE3 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 554 (actual)

## Conditions studied

- Cognitive/Functional Effects
- Metastatic Cancer
- Neurotoxicity
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** Memantine
- **OTHER:** Placebo
- **RADIATION:** Whole brain radiation therapy

## Key facts

- **NCT ID:** NCT00566852
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-04
- **Final completion:** 2016-12
- **Target enrollment:** 554 (ACTUAL)
- **Last updated:** 2017-08-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00566852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00566852, "Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00566852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*